SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom DuBois who wrote (4269)5/7/1998 5:35:00 PM
From: biodoc  Read Replies (1) of 6136
 
Believe it or not, such trials are sometimes not done with as much rigor as supposed, there have even been (rare) cases of fraud, but often there have been cases of poorly done marginal trials. Sometimes to find this it takes a full audit of all the clinical sites, which takes a long time. In addition, the manufacturing to GMP standards must be audited etc. usually the FDA will completely reanalyze the trial, (and sometimes the results don't agree with the sponsor's analysis). Two years, however, is on the long side for important (from a public health point of view) new drugs these days. In fact, if the review is fast tracked, it can take 6 mos or less.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News